Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0906587 on June 5, 2007

Published online before print June 5, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0906587v1
82/3/449    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomperts, B. N.
Right arrow Articles by Strieter, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomperts, B. N.
Right arrow Articles by Strieter, R. M.
(Journal of Leukocyte Biology. 2007;82:449-456.)
© 2007 by Society for Leukocyte Biology

Fibrocytes in lung disease

Brigitte N. Gomperts* and Robert M. Strieter{dagger},1

* Mattel Children’s Hospital, Department of Pediatrics, Division of Pediatric Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA; and
{dagger} Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA

1 Correspondence: Department of Medicine, University of Virginia School of Medicine, P.O. Box 800466, Charlottesville, VA 22908-0466, USA. E-mail: strieter{at}virginia.edu

Fibrocytes were first described over a decade ago as a population of cells in circulation with fibroblast-like properties, which were involved in tissue repair. Since that time, we have learned a significant amount about these bone marrow-derived cells, which contribute to wound healing and fibrosis. Fibrocytes express leukocyte markers such as CD34, CD45, and CD13 and also express mesenchymal markers such as pro-collagens I and III, vimentin, and fibronectin. In addition, they have been shown to express the chemokine receptors CXCR4 and CCR7, which appear to be important in cellular trafficking from the vascular to the extravascular compartment. Fibrocytes have been shown to contribute to a number of fibrotic disorders, and here, we review their involvement in lung diseases including pulmonary fibrosis, asthma, and vascular remodeling.

Key Words: chemokines • chemokine receptors • stem cells • progenitor cells • pulmonary fibrosis




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667.
[Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. D. Shao, R. Suresh, V. Vakil, R. H. Gomer, and D. Pilling
Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation
J. Leukoc. Biol., June 1, 2008; 83(6): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. M. Strieter
What Differentiates Normal Lung Repair and Fibrosis?: Inflammation, Resolution of Repair, and Fibrosis
Proceedings of the ATS, April 15, 2008; 5(3): 305 - 310.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Leukocyte Biology.